

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists


 Product Name
 :MK-0159

 Cat.No.
 :URK-V2530

 CAS No.
 : 2641484-61-7

 $\label{eq:molecular-weight} \begin{array}{ll} \mbox{Molecular Weight} & :400.49 \\ \mbox{Molecular Formula} & :C_{20}H_{24}N_4O_3S \end{array}$

Target : Solubility :



Biological Activity

MK-0159, also known as Balixafortide, is a novel and selective antagonist of the chemokine receptor CXCR4. Balixafortide also has potential utility as a stem cell mobilizer. By disrupting the CXCR4-SDF1 axis, Balixafortide has been shown to mobilize hematopoietic stem cells into peripheral blood, making them more available for collection in patients undergoing stem cell transplantation.

References

- 1. Zhang Z, Ni C, Chen W. et al. Balixafortide (MK-0466) as a monotherapy or combination therapy with eribulin mesylate for the treatment of advanced breast cancer. OncoTargets Ther. 2020;13:393-401.
- 2. Ishikawa T, Nakashima S, Namba T. et al. Balixafortide, a CXCR4 antagonist, suppresses tumor progression and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Surg Today. 2020 Oct;50(10):1224-1231.
- 3. Deng X, Ruan H, Zhang X. et al. Balixafortide, a CXCR4 antagonist, enhances the effect of chemotherapy and improves prognosis in advanced breast cancer patients. Front Oncol. 2020;10:43.
- 4. Fruehauf S, Seggewiss-Bernhardt R, Khandanpour C. et al. Balixafortide is a novel stem cell mobilizer with broad potential utility. Blood. 2018;132(Suppl 1):3034.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only! JACK@UREIKO-CHEM. COM